Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 522 across all filing types
Latest filing 2024-06-03 Regulatory Filings
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 99% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces new clinical data presented by Teva regarding the transition to UZEDY® for schizophrenia treatment. It contains forward-looking statements and contact information typical of a corporate announcement. Since it is an announcement of clinical/partner news rather than a formal regulatory filing like a 10-K, IR, or ER, and it doesn't fit the specific categories like DIRS, DIV, or CAP, it falls best under the general category for regulatory/corporate announcements that don't fit elsewhere, which is Regulatory Filings (RNS). It is not a short announcement pointing to a larger report, but the report itself (a press release).
2024-06-03 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "PRESS RELEASE" and announces new data presented by Teva (Medincell's partner) at a conference regarding a schizophrenia treatment (UZEDY®). It contains company updates, contact information, and standard forward-looking statements typical of a corporate announcement. Since it is an initial announcement of results/data presentation, and not a comprehensive periodic report (like 10-K or IR), nor a transcript (CT), nor a formal regulatory filing detailing a specific event like a dividend (DIV) or insider trade (DIRS), it best fits the category for initial financial/operational results announcements, which aligns with 'Earnings Release' (ER) for broad operational updates, or potentially 'Regulatory Filings' (RNS) as a general announcement. Given the content focuses on clinical data presentation and partnership updates rather than quarterly financial figures, it is a general corporate announcement. However, in the context of financial reporting categories, press releases announcing significant operational milestones or data presentations often fall under the broader umbrella of initial results/updates. Since 'ER' is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)', and this is an announcement of data presentation, the closest fit among the specific options that aren't purely administrative (like RPA or RNS) is often the general announcement category. Given the options, and that this is a press release announcing operational/clinical progress rather than a formal financial filing, 'RNS' (Regulatory Filings - general regulatory announcements and fallback) is the most appropriate classification for a non-standard, non-periodic corporate press release that doesn't fit the other specific codes.
2024-06-03 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 99% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and its primary content is an "Mise à jour du calendrier financier 2024" (Update to the 2024 financial calendar), detailing revised dates for the annual results, AGM, and semi-annual results. This is an announcement about future corporate events and reporting schedules, not the reports themselves (like 10-K or IR). Since it is an announcement regarding the timing and scheduling of corporate events/reports, it fits best under Report Publication Announcement (RPA). It is not a general regulatory filing (RNS) because RPA is more specific for announcements about report publication schedules.
2024-05-27 French
Inside Information / Other news releases
Report Publication Announcement Classification · 98% confidence The document is explicitly titled "PRESS RELEASE" and its primary content is an "Update of the 2024 financial calendar." It announces changes to the dates for the 'Annual results', 'General Meeting', and 'Half-Year results'. This document is not the actual financial report (10-K or IR) or the proxy statement (DEF 14A), but rather an announcement about the timing of future corporate events and reports. Since it is an announcement regarding the schedule of corporate reporting events, it fits best under the category for announcing the publication of reports, which is Report Publication Announcement (RPA). It is not a general regulatory filing (RNS) because RPA is more specific for scheduling announcements.
2024-05-27 English
Inside Information / Other news releases
Investor Presentation Classification · 95% confidence The document is explicitly titled "PRESS RELEASE" and announces that the CEO and CMO will present at the "2024 Jefferies Global Healthcare Conference." It provides details about the presentation time, location, and a link for remote access. It also mentions arranging 1x1 meetings. This type of communication, which announces management's participation in an external industry event (like a conference presentation) rather than releasing periodic financial results (ER/IR) or official regulatory filings (10-K/AR), is best classified as an Investor Presentation (IP) or a general announcement related to investor relations activities. Since the core purpose is to inform investors about an upcoming presentation where the company's portfolio and pipeline will be discussed, 'Investor Presentation' (IP) is the most fitting category, even though the document itself is a press release announcing the event, not the presentation slides themselves. However, given the options, this announcement serves the function of promoting investor engagement regarding the company's strategy and pipeline, which aligns closely with the intent of an Investor Presentation announcement. If 'Investor Presentation' (IP) is interpreted strictly as the slides, then 'Regulatory Filings' (RNS) might be a fallback, but IP captures the context better. Given the content focuses heavily on pipeline updates, partnerships, and future outlook presented at an investor conference, IP is selected.
2024-05-21 English
Informations privilégiées / Autres communiqués
Investor Presentation Classification · 99% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces that company executives will be presenting at the "Jefferies Global Healthcare Conference" on a specific date. It provides details for accessing the presentation webcast and arranging one-to-one meetings with management. This content—announcing participation in an external investor conference and providing access links—is characteristic of an Investor Presentation (IP) or a general announcement about investor relations activities. Since the core purpose is to inform investors about an upcoming presentation/event where company strategy and pipeline will be discussed, 'Investor Presentation' (IP) is the most fitting category, even though the document itself is a press release announcing the event rather than the presentation slides themselves. It is not a formal regulatory filing like 10-K or IR, nor is it a simple Earnings Release (ER) or a Report Publication Announcement (RPA) for a mandatory report.
2024-05-21 French

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.